Determining genetic risk for posttraumatic chronic pain and related neuropsychiatric disorders using polygenic risk scores. by Lobo, Jarred
Jarred Lobo
B.S. Neuroscience & B.A. Public Policy
Faculty Advisor: Sarah Linnstaedt
Anesthesiology Department
Determining genetic risk for posttraumatic chronic 
pain and related neuropsychiatric disorders using 
polygenic risk scores.
Overview
Background: Twin and family studies have reported a significant contribution 
of genetic factors to onset of chronic pain and related psychiatric disorders. 
Technological advancements now allow for the systematic testing of genetic 
variants across the genome for association with traits to better understand 
the cumulative effect of different alleles.
Research Question: Can a polygenic model be used to predict genetic risk for 
posttraumatic chronic pain and posttraumatic stress symptom development?
Purpose:
Health care providers may use polygenic risk scores as well as nongenetic risk 
factors to evaluate a patient’s risk of chronic pain in order to create an 
individualized treatment plan.
Figure 1. Year 1 Moderate Pain
Week 6 
Moderate Pain
Month 6 
Moderate Pain
Year 1
Moderate Pain
Variance explained 
by the PRS. 1.24% 1.47% 2.95%
P value of the model 
fit. 0.00649 0.00357 0.00003
Number of SNPs 
included. 1,392 1,848 1,205
Table 1. Genetic risk for posttraumatic chronic pain using 
polygenic risk scores for back pain.
GWAS Chronic Pain (Severe 7-10)
Depression 
(CESD 16)
PTSD 
(IESR PTSD)
Depression 0.57% 3.12%*** 2.81%***
Schizophrenia 1.08%* 2.26%* 1.99%**
Bipolar Disorder 0.67% 1.16%* 1.13%*
PTSD - - -
Multisite Chronic Pain 0.84%* 0.49% 0.72%
Back Pain 1.73%** 1.35%** 1.65%**
Chronic Back Pain 1.72%** 0.79%* 0.61%
Table 2. Comparison of variance explained by the PRS 
model at week 6 using various GWAS discovery datasets.
* p<0.05 ** p<0.01 *** p<0.001
Methods: Polygenic risk scores were generated using GWAS discovery datasets and the target dataset 
consisting of European individuals between 18 and 65 years of age who presented to the ED within 24 
hours of a motor vehicle collision. Phenotypes tested included pain intensity (scale from 0-10), 
depression (CESD scale), and PTSD (IESR scale). PRSice, polygenic risk score software, was used to 
calculate, evaluate, and plot the results of the analyses. 
Results: The variance explained by the PRS model for moderate 
posttraumatic chronic pain (4-10 on pain scale) ranged from 1-3% using 
polygenic risk scores for back pain (Table 1). As the polygenic risk score 
increased, the odds ratio for year 1 moderate pain generally increased 
(Figure 1). Similar results were observed when testing other GWAS 
discovery datasets and phenotypes (Table 2).
Conclusion: The polygenic risk scores quantify the cumulative effect of 
genetic variants that play a significant role in the development of 
posttraumatic chronic pain and related symptoms. Future research may 
combine these polygenic risk scores with nongenetic risk factors to 
predict individual susceptibility.
